Colloidal drug delivery systems have been extensively investigated as drug carriers for the
application of different drugs via different routes of administration. Systems, such as solid …

It is generally agreed that a bacteriophage-associated phenomenon was first
unambiguously observed one-hundred years ago with the findings of Twort in 1915. This …

Current treatment therapeutic approach for tuberculosis is the administration of first line
drugs in the form of tablets and capsules for 4–6 months. However, this approach leads to …

The purpose of the present research work was to explore chitosan nanoparticles (NPs) of a
novel anti-tubercular drug, bedaquiline (BDQ) in order to reduce dose and side effects …

Tuberculosis (TB) is a primordial infectious disease that mainly affects the lungs. M.
tuberculosis (Mycobacterium tuberculosis) is the etiological agent of TB and currently more …

Pharmacotherapy of tuberculosis is potentially more efficient when delivered by the inhaled
route than by the current oral and/or parenteral routes due to the higher concentration of …

Drug-resistant tuberculosis (DR-TB) is an emerging health problem, challenging the
effective control of global TB. Current treatment of DR-TB includes administration of multiple …

Tuberculosis is the second leading cause of death from infectious diseases. Although
antitubercular drugs have been traditionally administered orally, there is a growing interest …

Pulmonary delivery of drugs and vaccines is an established route of administration, with
particulate-based carriers becoming an attractive strategy to enhance the benefits of …

Not all of the issues impacting the success of tuberculosis (TB) treatment arise from
pathogen-related disease characteristics. Nowadays, there is an increasing awareness that …